The broad pathway analysis, using GSEA and the Hallmark gene sets, suggested that Tregs from patients with TP53 mutation have different metabolic features in comparison to control‐Tregs and/or to AML‐CTLs. This evidence concerns the gene TP53 and acute myeloid leukemia.